Bladder cancer data poise FerGene gene therapy to compete with Keytruda

Less than two weeks after its launch, Ferring’s gene therapy subsidiary has revealed data that suggest its nadofaragene firadenovec could compete with Keytruda in an early form of bladder cancer.

The adenovirus serotype 5 vector delivering IFNA2B appears to be at least as efficacious as the anti-PD-1 mAb from Merck & Co. Inc. (NYSE:MRK) to treat patients with Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC), and may have a safety advantage. Both therapies are under FDA review for the indication...